Curasight has announced that it will expand its focus area for its two modalities, uTRACE (diagnostics) and uTREAT (therapy). Two recent publications made by researchers at the Danish Rigshospitalet underscored the potential of Curasight’s technology when applied to Neuroendocrine tumours (NET), as well as head and neck cancer. Curasight will invest in these two indications, which adds further to its pipeline.

Link to the analysis